Overall, TIO3 as a vaccine adjuvant activated antitumor effector T cells and NK cells by inhibiting the immunosuppressive cytokine TGF-β2 and PD1 and PD-L1 expression on immune cells and tumor cells. Here, PDCD1 is linked to neoplasm.